-- Cutia Therapeutics' (HKG:2487) topical anesthetic CU-30101 was approved in China, the firm said in a Hong Kong bourse filing Thursday.
The medicine, a formulation of lidocaine and tetracaine cream, was approved based on the results of its phase 3 clinical trial, which showed the product worked as well as the reference drug Pliaglis.